[The comparative characteristics of the safety, immunogenic activity and prophylactic potency of the adult and children types of live influenza vaccine in schoolchildren aged 7-14 years].
In Russia for prevention of influenza in children, aged from 3 to 14 years, the children's live influenza vaccine (LIV), based upon A/Leningrad/134/47/57(H2N2) master strain (LIVI) is used. The need for double immunization appears to be one out of the faulties of this preparation. The study was aimed to comparing the safety, immunogenic activity and prevention of influenza by LIV for adults (LIVII) (A/Leningrad/134/17/57(H2N2 master strain) and LIVI in children aged from 7 to 17 years under similar administration schedule. The safety, the preventive efficacy, humoral and secretory immunity were studied. In total 2486 persons, including 539 children, twice inoculated with LIVI, 971 persons once inoculated with LIVII, and 840 treated by placebo were obserbed. From the data of the clinical observations during 7 days after immunization both vaccines appeared to be low reactogenic. The LIVII advantages in induction of the humoral and secretory antibodies in comparison with children's vaccine had been revealed. Both vaccines were highly efficacious, the efficiency of both preparations was more pronounced after serologic correction of the diagnosis. The results obtained permit to recommend the single immunization by the variant of LIV at the base on A/Leningrad/134/17/57/(H2N2) master strain for prevention of influenza in school children.
Grigor'eva
E P
EP
Desheva
Iu A
IuA
Donina
S A
SA
Naĭkhin
A N
AN
Rekstin
A R
AR
Barantseva
I B
IB
Zavitkova
E A
EA
Moskvicheva
T M
TM
Zhavoronkov
V G
VG
Rudenko
L G
LG
D000281:Administration, Intranasal; D000293:Adolescent; D000914:Antibodies, Viral / Q000032:analysis; D002648:Child; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007115:Immunization Schedule; D007124:Immunoenzyme Techniques; D007071:Immunoglobulin A, Secretory / Q000032:analysis; D007251:Influenza, Human / Q000276:immunology / Q000517:prevention & control*; D009297:Nasal Mucosa / Q000276:immunology / Q000378:metabolism; D009975:Orthomyxoviridae / Q000276:immunology*; D012426:Russia; D014505:Urban Population; D014611:Vaccination; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000276:immunology; D014765:Viral Vaccines / Q000008:administration & dosage* / Q000276:immunology
D000914:Antibodies, Viral; D007071:Immunoglobulin A, Secretory; D014613:Vaccines, Attenuated; D014765:Viral Vaccines